Author profile
Dave’s short bio here – blah
This is Dave’s bio blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah blah
“Achieving successful medical technology commercialization and market access requires a highly sophisticated ecosystem of partners, and we have assembled the world’s leading regulatory, technology, product development, clinical and market access service providers to address the entire lifecycle of a medtech startup,” said Paul Grand, founder and CEO of MedTech Innovator.
Capgemini announced on Monday that it had made a breakthrough in generative biology, also known as engineering or synthetic biology, at its deep tech powerhouse Cambridge Consultants. The news was been widely picked up, including by PharmaTimes
Capgemini’s new patent-pending generative AI uses specialized large language models to accelerate the bioeconomy and biotechnology sector by drastically reducing the time and resources needed for research and development.